Proquin Xr Patent Expiration

Proquin Xr is a drug owned by Depomed Inc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 20, 2020. Details of Proquin Xr's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6488962 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Jun, 2020

(4 years ago)

Expired
US6340475 Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(8 years ago)

Expired
US6635280 Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(8 years ago)

Expired
US5972389 Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
Sep, 2016

(8 years ago)

Expired


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Proquin Xr and ongoing litigations to help you estimate the early arrival of Proquin Xr generic.

Proquin Xr's Litigations

Proquin Xr been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 17, 2014, against patent number US6635280. The petitioner Endo Pharmaceutical Inc. et al., challenged the validity of this patent, with Depomed, Inc. as the respondent. Click below to track the latest information on how companies are challenging Proquin Xr's patents.

Last updated on December 10, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6340475 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Final Written Decision
(21 Sep, 2015)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6340475 January, 2014 FWD Entered
(08 Jul, 2015)
Depomed, Inc. Purdue Pharma L.P.
US6635280 January, 2014 FWD Entered
(08 Jul, 2015)
DepoMed, Inc. Purdue Pharma L.P.
US6340475 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.
US6635280 April, 2014 Institution Denied
(29 Sep, 2014)
Depomed, Inc. Endo Pharmaceutical Inc. et al.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Proquin Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Proquin Xr's family patents as well as insights into ongoing legal events on those patents.

Proquin Xr's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Proquin Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 20, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Proquin Xr Generic API suppliers:

Ciprofloxacin Hydrochloride is the generic name for the brand Proquin Xr. 27 different companies have already filed for the generic of Proquin Xr, with Rising having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Proquin Xr's generic

Alternative Brands for Proquin Xr

Proquin Xr which is used for treating uncomplicated urinary tract infections., has several other brand drugs using the same active ingredient (Ciprofloxacin Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Bayer Hlthcare
Cipro Xr
Laboratorios Salvat
Otovel
Sandoz
Cipro Hc


Apart from brand drugs containing the same ingredient, some generics have also been filed for Ciprofloxacin Hydrochloride, Proquin Xr's active ingredient. Check the complete list of approved generic manufacturers for Proquin Xr





About Proquin Xr

Proquin Xr is a drug owned by Depomed Inc. It is used for treating uncomplicated urinary tract infections. Proquin Xr uses Ciprofloxacin Hydrochloride as an active ingredient. Proquin Xr was launched by Depomed Inc in 2005.

Approval Date:

Proquin Xr was approved by FDA for market use on 19 May, 2005.

Active Ingredient:

Proquin Xr uses Ciprofloxacin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Ciprofloxacin Hydrochloride ingredient

Treatment:

Proquin Xr is used for treating uncomplicated urinary tract infections.

Dosage:

Proquin Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 500MG BASE TABLET, EXTENDED RELEASE Discontinued ORAL